866-997-4948(US-Canada Toll Free)

pSivida Corp. (PSDV) - Product Pipeline Analysis

Published By :

GlobalData

Published Date : Oct 2012

Category :

Competitive Analysis

No. of Pages : 55 Pages


pSivida Corp. (pSivida) is a drug research and development company based in the US. The company develops tiny, sustained release drug delivery products to the healthcare sector. It develops drug delivery technologies that are used for the treatment of diseases such as chronic eye disease, diabetic macular edema, inoperable pancreatic cancer and numerous other applications. The companys product pipeline includes luvien, Retisert, Vitrasert and BrachySil and the core drug delivery technologies of the company include Durasert, BioSilicon and CODRUG. The companys trademarks include Medidur, Durasert, Tethadur, BioSilicon, BrachySil and CODRUG. The partners of the company include Pfizer, Alimera Sciences, Intrinsiq Materials Cayman Limited and Bausch & Lomb. pSivida principally operates in the UK and the US. pSivida is headquartered in Watertown, Maryland, the US.

This report is a source for data, analysis and actionable intelligence on the pSivida Corp. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

Scope

  • Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
  • Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
  • Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
  • Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
  • Data on relevant clinical trials and product patent details, wherever applicable.
  • Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
  • Design and develop your product development, marketing and sales strategies.
  • Exploit M&A opportunities by identifying market players with the most innovative pipeline.
  • Develop market-entry and market expansion strategies.
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Develop competition strategies by identifying the status and likely launch of your competitors pipeline products through review of the clinical trials, stage and phase of development, etc.
  • Which are the next high-value products that your competitor would add in its portfolio? identify, understand and capitalize.
Table of Content

Table of Contents 2
List of Tables 4
List of Figures 5

pSivida Corp. - Business Description 6

Key Facts 7
pSivida Corp. - Major Products and Services 8
pSivida Corp. Pipeline Products by Equipment Type 9
pSivida Corp. Pipeline Products by Development Stage 11
pSivida Corp. Pipeline Products by Therapy Area 13
pSivida Corp. Pipeline Products by Trial Phase 15
pSivida Corp. Pipeline Products by Milestone Summary 17
BrachySil 20
BrachySil Product Status 20
BrachySil Product Description 20
BrachySil Product Milestone 20
BrachySil Clinical Trial 21
BrachySil Product Patent Details 24
Durasert - Posterior Uveitis 29
Durasert - Posterior Uveitis Product Status 29
Durasert - Posterior Uveitis Product Description 29
Durasert - Posterior Uveitis Product Milestone 29
ILUVIEN Injection System 31
ILUVIEN Injection System Product Status 31
ILUVIEN Injection System Product Description 31
ILUVIEN Injection System Clinical Trial 31
ILUVIEN Injection System Product Patent Details 36
Latanoprost Implant 37
Latanoprost Implant Product Status 37
Latanoprost Implant Product Description 37
Latanoprost Implant Product Milestone 37
Tethadur System 39
Tethadur System Product Status 39
Tethadur System Product Description 39
Tethadur System Product Patent Details 39
pSivida Corp. - Key Competitors 45
pSivida Corp. - Key Employees 46
pSivida Corp. - Key Employee Biographies 47
pSivida Corp. - Locations And Subsidiaries 48
Head Office 48
Other Locations & Subsidiaries 48
Recent Developments 49
pSivida Corp., Recent Developments 49
Sep 24, 2012: Psivida Reports Revenue Of $3.5m In Fiscal 2012 49
Jul 30, 2012: pSivida Announces Tech Evaluation Agreement For Tethadur Protein/Antibody Delivery System 50
Jun 28, 2012: pSivida Announces Enrollment Of First Patient In Uveitis Trial 50
Jun 06, 2012: pSivida Announces Issuance Of US Patent For Inserter To Be Used In Planned Phase III Uveitis Trials 50
May 09, 2012: psivida Reports Q3 Fiscal 2012 Results 51
Mar 13, 2012: pSivida Announces Second Tech Evaluation Agreement With Neuron Systems For BioErodible Durasert Technology 51
Mar 06, 2012: pSivida Names Douglas Godshall To Board Of Directors 52
Feb 08, 2012: pSivida Reports Q2 Fiscal 2012 Results 52
Nov 07, 2011: pSivida Reports Revenues Of $1.7m In Q1 Fiscal 2012 53
Sep 12, 2011: psivida Reports Total Revenues Of $5m In Fiscal 2011 53

Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Table


pSivida Corp., Key Facts 1
pSivida Corp. Key Pipeline Products by Equipment Type 1
pSivida Corp. Key Pipeline Products by Therapy Area 1
pSivida Corp. Key Pipeline Products by Development Stage 1
pSivida Corp. Key Pipeline Products by Trial Phase 1
pSivida Corp., Key Facts 7
pSivida Corp., Major Products and Services 8
pSivida Corp. Number of Pipeline Products by Equipment Type 9
pSivida Corp. Pipeline Products by Equipment Type 10
pSivida Corp. Number of Pipeline Products by Development Stage 11
pSivida Corp. Pipeline Products by Development Stage 12
pSivida Corp. Number of Pipeline Products by Therapy Area 13
pSivida Corp. Pipeline Products by Therapy Area 14
pSivida Corp. Number of Pipeline Products by Trial Phase 15
pSivida Corp. Pipeline Products by Trial Phase 16
pSivida Corp. Number of Pipeline Products By Milestone Summary 17
pSivida Corp. Pipeline Products by Milestone Summary 18
BrachySil - Product Status 20
BrachySil - Product Description 20
BrachySil - Product Milestone 20
BrachySil - A Study of the Safety Profile of Three Escalating Radioactivity Levels of 32P BioSilicon Delivered With the SIMPL Needle as Intratumoural Implantations in Patients With Unresectable Hepatocellular Carcinoma 21
BrachySil - European Pancreatic Cancer Study on Biosilicon - BrachySil 23
BrachySil - Patent Details1 24
BrachySil - Patent Details2 25
BrachySil - Patent Details3 25
BrachySil - Patent Details4 26
BrachySil - Patent Details5 26
BrachySil - Patent Details6 27
BrachySil - Patent Details7 27
BrachySil - Patent Details8 28
Durasert - Posterior Uveitis - Product Status 29
Durasert - Posterior Uveitis - Product Description 29
Durasert - Posterior Uveitis - Product Milestone 29
ILUVIEN Injection System - Product Status 31
ILUVIEN Injection System - Product Description 31
ILUVIEN Injection System - A Single Masked, Randomized Comparison of the Safety and Efficacy of 0.2 and 0.5 g/Day Fluocinolone Acetonide/Medidur in Patients With Exudative Age Related Macular Degeneration Who Have Received Lucentis 31
ILUVIEN Injection System - First Human Pharmacokinetic(1) (Pk) Study Of Medidur FA 33
ILUVIEN Injection System - Phase III Clinical Trial To Investigate The Use of Iluvien in Diabetic Macular Edema 34
ILUVIEN Injection System - Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study 35
ILUVIEN Injection System - Patent Details1 36
Latanoprost Implant - Product Status 37
Latanoprost Implant - Product Description 37
Latanoprost Implant - Product Milestone 37
Tethadur System - Product Status 39
Tethadur System - Product Description 39
Tethadur System - Patent Details1 39
Tethadur System - Patent Details2 40
Tethadur System - Patent Details3 40
Tethadur System - Patent Details4 41
Tethadur System - Patent Details5 41
Tethadur System - Patent Details6 42
Tethadur System - Patent Details7 43
Tethadur System - Patent Details8 44
pSivida Corp., Key Employees 46
pSivida Corp., Key Employee Biographies 47
pSivida Corp., Subsidiaries 48

List of Chart


pSivida Corp. Key Pipeline Products by Equipment Type 1
pSivida Corp. Pipeline Products by Equipment Type 9
pSivida Corp. Pipeline Products by Development Stage 11
pSivida Corp. Pipeline Products by Therapy Area 13
pSivida Corp. Pipeline Products by Trial Phase 15
pSivida Corp. Pipeline Products by Milestone Summary 17

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *